M. ANANDAM & CO.,

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To

The Board of Directors of

Combat Drugs Limited

We have reviewed the accompanying Statement of Unaudited Financial Results of Combat Drugs Limited for

the Quarter ended 30th June, 2016. This statement is the responsibility of the company's Management and

has been approved by the Board of Directors. Our responsibility is to issue a report on these financial

statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of

InterIm Financial Information Performed by the Independent Auditor of the Entity"issued by the Institute of

Chartered Accountants of India. This standard requires that we plan and perform the review to obtain

moderate assurance as to whether the financial statements are free of material misstatement. A review is

limited primarily to inquiries of company personnel and analytical procedures applied to financial data and

thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express

an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the

accompanying statement of unaudited financial results prepared in accordance with applicable accounting

standards and other recognized accounting practices and policies has not disclosed the information required

to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015, read with Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 and SEBI Circular

No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it

contains any material misstatement.

For M. Anandam& Co.,

Chartered Accountants

(FRN: 000125S)

A.V.Sadasiva

Partner

Membership No.018404

Place: Hyderabad

Date: 13th August, 2016

COMBAT DRUGS LIMITED

(CIN NO. CL23230TG1986PLC006781)

Regd.off: D.No.9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Boduppal (V) Ranga Reddy Dist. Hyderabad Telangana - 500 039

Ph:040-65523363 URL: www.combatdrugs.in Mail: info@combatdrugs.in

(CIN NO. CL232301G1986PLC006781)		OHARTER ENDER		ibatarago.iii
UN-AUDITED FINANCIAL RI		1		Describera Voor and
Particulars	Quarter ended	Preceeding Qtr	Prv Year to date	Previous Year end
Amount - Rs. In lakhs	30.06.2016	31.03.2016	30.06.2015	31.03.2016
	Unaudited	Audited	Unaudited	Audited
PART - I				-
1. Income from Operations				
1 (a) Net Sales/Income from Operations (net of	3.07	5.46	2.46	22.30
excise duty)	0.00	0.00	0.00	0.00
(b) Other Operating Income	0.00	0.00	0.00	22.30
Total income from operations (net)	3.07	5.46	2.46	22.30
2 Expenses	0.57	2.24	4.75	11.30
a. Cost of materials consumed	2.57	3.21	1.75	0.00
b. Purchase of stock-in-trade	0.00	0.00	0.00	0.00
c. Changes in inventories of Finished goods, work- in-progress and stock-in-trade	0.00	0.00	0.00	0.00
d. Employees benefits expense	4.08	7.79	1.53	12.38
e. Depreciation	0.00	0.00	2.85	8.56
f. Expired Stocks	0.00	11.11	0.00	39.92
g. Other expenses	4.56	60.53	5.73	78.46
Total	11.21	82.64	11.86	150.62
3 Profit / (Loss) from Operations before Other Income, finance costs and Exceptional Items (1-	(8.14)	(77.18)	(9.40)	(128.32)
4 Other Income	0.00	0.15	0.00	0.55
Profit / (Loss) from ordinaty activities before finance costs and Exceptional Items (3+4)	(8.14)	(77.03)	(9.40)	(127.77)
6 Finance costs	0.00	0.00	0.00	0.00
7 Profit / (Loss) from ordinary activities after finance costs but before Exceptional Items (5-	(8.14)	(77.03)	(9.40)	(127.77)
8 Exceptional items	0.00	0.00	0.00	0.00
9 Profit / (Loss) from Ordinary Activities before	(8.14)	(77.03)	(9.40)	(127.77)
tax (7+8)		`	0.00	0.00
10 Tax expense .	0.00	0.00	. 0.00	0.00
11 Net Profit / (Loss) from Ordinary Activities after tax (9+10)	(8.14)	(77.03)	(9.40)	(127.77)
12 Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00
13 Net Profit / (Loss) for the period (11-12)	(8.14)	(77.03)	(9.40)	(127.77)
14 Share of Profit / (Loss) of associates	0.00	0.00	0.00	0.00
15 Minority interest	0.00	0.00	0.00	0.00
Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	(8.14)	(77.03)	(9.40)	(127.77)
17 Paid-up equity share capital-Face value Rs.10/-	800.00	800.00	800.00	800.00
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00
19 Earnings per Share(before extraordinary items)				
(a) Basic	(0.10)	(0.96)	(0.12)	(1.60)
(b) Diluted	(0.10)	(0.96)	(0.12)	(1.60)
ii) Earning per share(after extraordinary items)	(37.3)	(====)		
(a) Basic	(0.10)	(0.96)	(0.12)	(1.60)
(b) Diluted	(0.10)	(0.96)	(0.12)	(1.60)
Notes	(5.10)	(5.00)	(2.1.2)	

Notes

1 The above Financial Results as recommended by the Audit Comittee were considered and approved by the Board of Directors at their meeting held on 13th Aug, 2016.

The Company is operating in only one segment.

Previous year/s / period's figures have been regrouped / rearranged / recasted wherever necessary.

Place: Hyderabad Date: 13-08-2016

TELANGE OF THE Board of Directors

MANAGING DIRECTOR